Theresa May writes to FSCS over Lehman-backed NDFA plans

Laura Miller
clock

Home secretary Theresa May has written to the Financial Services Compensation Scheme about its decision to compensate some Lehman-backed NDFA structured products but not others.

Billions of dollars of the US investment bank's debt were packaged as structured products and sold to retail savers worldwide. When Lehmans collapsed in September 2008, the investments became worthless. About 2,000 investors in 'Capital at Risk' plans run by failed firms Arc, NDF Administration and Defined Returns Limited (DRL) have been told by the FSCS that they are not eligible to claim compensation for their losses. The son of one Capital at Risk investor, who is 93 years old and invested £50,000 without the advice of an IFA, who lives in May's constituency, has met with the home ...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot